Name: Big Pharma, big Greed: The Inside Story of one Lawyer’S Battle to Stem the Flood of Dangerous Medicines and Protect Public Health (en Inglés)
Price: 30.31 USD
Availability: InStock
Author: Stephen Sheller; Sidney Kirkpatrick; Christopher Mondics
ISBN: 9781947492257

portada Big Pharma, big Greed: The Inside Story of one Lawyer’S Battle to Stem the Flood of Dangerous Medicines and Protect Public Health (en Inglés)

Big Pharma, big Greed: The Inside Story of one Lawyer’S Battle to Stem the Flood of Dangerous Medicines and Protect Public Health (en Inglés)

Formato

Libro Físico

Autor

Editorial

Idioma

Inglés

N° páginas

154

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.9 cm

Peso

0.24

ISBN13

9781947492257

Categorías

Derecho del consumo y protección de consumidores y usuarios

Big Pharma, big Greed: The Inside Story of one Lawyer’S Battle to Stem the Flood of Dangerous Medicines and Protect Public Health (en Inglés)

Sidney Kirkpatrick (Autor) · Christopher Mondics (Autor) · Stephen Sheller (Autor) · Strong Arm Press · Tapa Blanda

Libro Nuevo Importado *

Envío: 20 a 27 días háb.

$ 53.09$ 30.31

-43%

* Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 30.31

Se enviará desde nuestra bodega entre el Viernes 15 de Mayo y el Miércoles 27 de Mayo

Más Info

Agregar a lista de deseos

Reseña del libro "Big Pharma, big Greed: The Inside Story of one Lawyer’S Battle to Stem the Flood of Dangerous Medicines and Protect Public Health (en Inglés)"

In "Big Pharma, Big Greed: The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health", Stephen Sheller tells a tale that is at once deeply personal but also with wide repercussions for the U.S. health care system and the hundreds of millions of Americans whose lives literally depend on it. In the book, Sheller not only recounts his major litigation battles but also makes sweeping proposals for industry reform. To restore regulatory credibility, Sheller proposes that responsibility for testing new medicines be taken away from the industry and given over to hospitals and other public entities partnering with government regulators. Pharmaceutical companies that betray the public trust would risk government- initiated dissolution. Harsh medicine to be sure, but Sheller believes entirely appropriate to the underlying malady.